A new procedure which combines LASIK and corneal cross-linking (Lasik Xtra Ò ) has been proposed as an alternative to traditional LASIK. It is aimed at restoring strength to the cornea, increasing stability in visual outcomes, increasing the accuracy of the refractive correction, and potentially lowering enhancement rates. This article reviews the current clinical evidence which has been published on the topic and reviews both the safety and efficacy argument for the procedure.
INTRODUCTION
Laser in situ keratomileusis (LASIK) is the most commonly performed refractive procedure in the United States, due in part to rapid visual recovery, minimal postoperative discomfort, and perceived improvement in patient quality of life [1] . However, despite advancements in femtosecond and excimer laser technology, and the adoption of more thorough diagnostic screening approaches, the procedure is not without impact on the biomechanical properties of the cornea. LASIK requires the creation of a flap and the removal of tissue, which may result in weakening of the anterior corneal stroma and decreasing overall corneal rigidity [2, 3] . This may be one mechanism that contributes to regression of refractive effect leading to ''enhancement'' (retreatment) procedures [4] . In rare cases, weakening can result in corneal ectasia and associated progressive degradation of vision [5] . As the effects of corneal weakening become better understood, effort is being applied to reduce impact on treatment outcomes. A very promising approach for restoration of corneal stability in these instances is riboflavin/ultraviolet A (UVA)-mediated corneal cross-linking (CXL).
CXL was first introduced in the late 1990s in
Dresden, Germany as a means of stabilizing the cornea, and the procedure has been rapidly adopted outside of the United States as a standard therapy for treatment of keratoconus (KC) and iatrogenic corneal ectasia [6] . The conventional CXL treatment approach for KC and ectasia has been shown to not only stabilize the cornea, but to result in corneal flattening, on the order of more than 1 D [7] . Many of the mechanisms and controls underlying CXL have been studied and predictive chemical [8] and biomechanical methods [9, 10] have been developed to better understand CXL. Details of the mechanisms underlying CXL are an area of fertile research, beyond the scope of this paper.
While the initial cross-linking technique utilized a low irradiance (3 mW/cm 2 ) UVA source requiring 30 min of irradiation time, accelerated cross-linking techniques, first proposed 7 years ago [11] , have more recently been introduced clinically to dramatically shorten procedure time [12] . Accelerated cross-linking using higher irradiance (30 mW/   cm 2 ) has been demonstrated to be effective at stabilizing and reducing corneal curvature in patients with keratoconus or iatrogenic corneal ectasia. Studies have shown that its effects are equivalent to conventional CXL in terms of efficacy at stabilizing the cornea, with an equivalent or better safety profile [13] [14] [15] .
LASIK in combination with CXL (Lasik Xtra Ò Avedro, Massachusetts, USA) is an alternative to traditional LASIK aimed at restoring strength to the cornea, increasing stability in visual outcomes, increasing the accuracy of the refractive correction, and potentially lowering enhancement rates. Corneal cross-linking has been shown to enhance the structural integrity of the cornea, in both animal studies [16] and in clinical practice, stiffening the cornea [17] and halting the progression of ectasia such as keratoconus [18] . It is logical to anticipate that stiffening a cornea, which has been structurally weakened by LASIK, through the addition of CXL, may minimize the negative effects associated with this biomechanical compromise. In other words, the aim of Lasik Xtra is to further reduce the rare incidence of iatrogenic ectasia, as well as to reduce the rate of treatment regression and enhancements.
Although not yet approved in the United
States, Lasik Xtra is in clinical use in more than 50 countries worldwide. The procedure is frequently performed on patients who are considered good candidates for the LASIK procedure, but may fall into categories associated with greater risk of post-LASIK regression: those with hyperopia [19] high amounts of myopia [20] , younger patients and those with borderline-predicted residual stromal bed thickness [21] . This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. 
THE LASIK XTRA PROCEDURE

CLINICAL OUTCOMES
A number of clinical studies have been performed to evaluate the performance of Lasik Xtra using a variety of treatment methods, examining changes in tissue morphology, refractive stability and treatment safety. These studies are summarized in Table 1 .
Tissue Morphology
In a case report using laser scanning in vivo confocal microscopy to evaluate a patient treated with Lasik Xtra, Mazzotta et al. [26] observed morphological changes including hyper-reflectivity and keratocyte apoptosis, 
Increased Stability in Visual Outcomes
International studies have shown the benefits of Lasik Xtra for patients with high myopic and high hyperopic corrections.
Kanellopoulos [27] reported 2-year follow-up on a cohort of 34 consecutive patients treated using Lasik Xtra in conjunction with bilateral, topography-guided Hyperopic LASIK treatment.
Hyperopic LASIK is well understood to be subject to significant regression of LASIK treatment effect. In this study, patients received LASIK ? CXL in one eye (CXL group) and LASIK without CXL in the contralateral eye 
Treatment Safety
CXL treatment for KC and corneal ectasia has been found to have a low rate of side effects. It is not surprising that, as Lasik Xtra produces similar tissue effects to these treatments, and uses lower doses for treatment effect, the safety profile is favorable. In addition to the studies described above, in which there were no side effects beyond those typically associated with LASIK treatment, several papers have looked at the safety of this prophylactic treatment.
The earliest study was a pilot fellow-eye case series in 4 subjects with 12-month follow-up conducted in Turkey [30] . At the 12-month follow-up, the Lasik Xtra group had a UDVA and manifest refraction equal to or better than those in the LASIK-only group. No eye lost 1 or more lines of spectacle-corrected distance visual acuity at the final visit. The endothelial cell loss in the Lasik Xtra eye was not greater than in the fellow eye. No side effects were associated with either procedure.
A Japanese study [31] found Lasik Xtra to be The line was well-defined in two eyes (8.3%) and faint in 21 eyes (87.5%). The study found no significant differences in corrected and uncorrected distance visual acuity, manifest refraction spherical equivalent, endothelial cell density, or 37 parameters dynamic bidirectional applanation readings.
Additionally, in another large study of routinely treated subjects [21] , 601 Lasik Xtra patients showed stable uncorrected distance visual acuity over 1 year of follow-up. These patients showed no significant changes in manifest refraction spherical equivalent and average K readings during the 1-year follow-up. 
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